Stockscreener 앱 받기
0.273
7.46%
-0.022
시간 외 거래:
.26
-0.013
-4.76%
전일 마감가:
$0.295
열려 있는:
$0.2845
하루 거래량:
5.44M
Relative Volume:
0.43
시가총액:
$12.11M
수익:
$1.04M
순이익/손실:
$-67.50M
주가수익비율:
-0.142
EPS:
-1.9222
순현금흐름:
$-60.67M
1주 성능:
+13.75%
1개월 성능:
+9.90%
6개월 성능:
-55.27%
1년 성능:
-91.90%
1일 변동 폭
$0.2641
$0.2973
1주일 범위
$0.2325
$0.5476
52주 변동 폭
$0.198
$5.14
Vistagen Therapeutics Inc Stock (VTGN) Company Profile
명칭
Vistagen Therapeutics Inc
전화
650-577-3600
주소
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare VTGN vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VTGN
Vistagen Therapeutics Inc
|
0.273 | 12.11M | 1.04M | -67.50M | -60.67M | -1.9222 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-17 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-12-17 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2025-12-17 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-12-17 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-12-07 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-08-07 | 업그레이드 | Maxim Group | Hold → Buy |
| 2022-07-22 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-22 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2022-07-22 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-05-20 | 개시 | Robert W. Baird | Outperform |
| 2021-02-18 | 개시 | Jefferies | Buy |
| 2021-01-04 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-06-27 | 개시 | Maxim Group | Buy |
| 2018-02-08 | 재확인 | Chardan Capital Markets | Buy |
| 2017-03-28 | 개시 | Maxim Group | Buy |
모두보기
Vistagen Therapeutics Inc 주식(VTGN)의 최신 뉴스
Vistagen Therapeutics, Inc. (VTGN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Form 8K VistaGen Therapeutics Inc For: 25 September By Investing.com - Investing.com Nigeria
VistaGen Updates Strategy for Pherine-Based CNS Therapies - TipRanks
Three anxiety drug trials missed their goals. Vistagen (VTGN) proposes another after one met its goal. - Stock Titan
Vistagen Therapeutics, Inc. (VTGN) stock price, news, quote and history - Yahoo Finance Singapore
Vistagen Therapeutics Shares Positive Fasedienol Nasal Spray Data at Psych Congress 2026 - Kalkine Media
Vistagen Presents Fasedienol Subgroup Data in Severe Social Anxiety Disorder - Yahoo Finance
Vistagen (VTGN) Reports Positive Phase 3 Social Anxiety Data Ami - GuruFocus
Vistagen presents exploratory data on social anxiety treatment - Investing.com India
Vistagen presents exploratory data on social anxiety treatment By Investing.com - Investing.com Canada
A Phase 3 trial missed its main goal overall, despite a possible nasal-spray benefit in very severe cases. - Stock Titan
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Vistagen Therapeutics, Inc. Stock Price Prediction: Today, Tomorrow, Next Week (VTGN) - Traders Union
Vistagen Therapeutics Surges on Positive Extension Data for Fasedienol - Quiver Quantitative
Penny Stock Vistagen Analyst Highlights Caution after Anxiety Data - Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
$VistaGen Therapeutics (VTGN.US)$ dont panic analyst said is 1 - Moomoo
Top Premarket Gainers - Yahoo Finance
VistaGen Reports Positive Long-Term Fasedienol Anxiety Data - TipRanks
Vistagen reports positive open-label extension safety and exploratory efficacy for fasedienol in social anxiety - TradingView
Year‑long nasal spray use at Vistagen (NASDAQ: VTGN) lowers social anxiety scores as FDA talks approach - Stock Titan
Good Luck~ $VistaGen Therapeutics (VTGN.US)$ - Moomoo
Vistagen Announces Preliminary Positive Data from - GlobeNewswire
This Stock Lost 71% Of Value After Anxiety Therapy Missed Key Goals – But Retail Believes It’s Oversold, Says Won’t Panic-Sell - Stocktwits
Vistagen Therapeutics shareholders elect board members and approve key proposals By Investing.com - Investing.com Australia
Form 8K VistaGen Therapeutics Inc For: 11 September By Investing.com - Investing.com Nigeria
VistaGen Stockholders Reaffirm Board, Governance and Oversight - TipRanks
Vistagen Therapeutics shareholders elect board members and approve key proposals - Investing.com India
Stockholders at Vistagen (NASDAQ: VTGN) back board slate, executive pay and KPMG - Stock Titan
Vistagen to Present at Psych Congress 2026 - GlobeNewswire
VistaGen Therapeutics Inc. (VTGN) Peer Comparison – Compare with Others - Value Research
VistaGen Therapeutics Inc. (VTGN) Key Financial Ratios – Valuation, Profitability & More - Value Research
Vistagen Therapeutics (VTGN) Slides 4.31% to $0.24, Testing Key Support at $0.23Box Spread - vinanet.vn
Vistagen Therapeutics Lawsuit: Company Seeks Dismissal of Investor Securities Claims - TipRanks
VistaGen Therapeutics Inc. (VTGN) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Vistagen Therapeutics Q2 2026 Earnings: Narrower Loss Beats Estimates, Stock Slips 1.56%CEO Earnings Statement - dars.gov.et
Vistagen (VTGN) Trading: Gains 1.20% to Reach $0.24 on the Day; the Current Price Sits Inside the Supplied Technical Range in the Available RecordLeveraged ETF Flow - vinanet.vn
VistaGen Therapeutics earnings missed by $0.05, revenue topped estimates - Investing.com Canada
VistaGen Therapeutics (VTGN) Institutional Ownership 2026 - MarketBeat
Vistagen Therapeutics: Runway To Fund Operations Into 2027 >VTGN - Moomoo
William Blair Maintains VistaGen Therapeutics(VTGN.US) With Hold Rating - Moomoo
Vistagen Therapeutics Releases Q1 2027 Financial Results - AlphaStreet
Vistagen Therapeutics (VTGN): OrbiMed reports 0.0% beneficial ownership in latest 13G/A - Stock Titan
Vistagen Therapeutics (VTGN) investor Chen Yu reports 6.7% warrant-based stake - Stock Titan
Vistagen Therapeutics (VTGN) flags going concern risk amid Q1 loss and Nasdaq pressure - Stock Titan
Vistagen Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2026 - marketscreener.com
Vistagen Therapeutics (VTGN) investor reports 4.24M-share, 9.9% stake - Stock Titan
Form 8K VistaGen Therapeutics Inc For: 14 August By Investing.com - Investing.com India
Vistagen Reports $1.5 Million Revenue and $13.0 Million Quarterly Net Loss - Moomoo
Vistagen reports Q1 FY2027: $1.48M revenue, $13.0M net loss, $31.7M cash at June 30, 2026 - TradingView
VistaGen Therapeutics | 8-K: Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update - Moomoo
Vistagen Therapeutics Inc (VTGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.06%
2.55%
자본화:
|
볼륨(24시간):